{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:54:49Z","timestamp":1781513689769,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K08CA276706-02"],"award-info":[{"award-number":["5K08CA276706-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.surg.2025.109907","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:42:38Z","timestamp":1765514558000},"page":"109907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Does neoadjuvant systemic therapy in clinical T1\u20132 N0 human epidermal growth factor receptor 2\u2013positive breast cancer increase the extent of axillary surgery?"],"prefix":"10.1016","volume":"191","author":[{"given":"Christine C.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Irene C.","family":"Lloren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiang-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne N.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mediget","family":"Teshome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler S.","family":"Cortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2025.109907_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2025.109907_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/cco-20-123","article-title":"Neoadjuvant treatment for HER2-positive breast cancer","volume":"9","author":"Takada","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-025-07750-2","article-title":"National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative HER2-positive breast cancer: the impact of the KATHERINE trial","volume":"212","author":"Cohen","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2025.109907_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13058-019-1186-0","article-title":"A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.surg.2025.109907_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.29271\/jcpsp.2019.02.159","article-title":"Pathologic complete response in HER2-positive breast cancer patients receiving trastuzumab in neoadjuvant setting","volume":"29","author":"Sheikh","year":"2019","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.surg.2025.109907_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100433","article-title":"Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials","volume":"7","author":"Guarneri","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.surg.2025.109907_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"Nitz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.surg.2025.109907_bib8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","volume":"62","author":"Harbeck","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.surg.2025.109907_bib9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.21037\/gs-24-159","article-title":"Shifting neoadjuvant chemotherapy treatment paradigms for breast cancer and its impact on axillary nodal management for clinically node-negative patients","volume":"13","author":"Cortina","year":"2024","journal-title":"Gland Surg"},{"key":"10.1016\/j.surg.2025.109907_bib10","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/cncr.34750","article-title":"Nodal positivity and systemic therapy among patients with clinical T1\u2013T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts","volume":"129","author":"Weiss","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2025.109907_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clbc.2024.03.004","article-title":"Systemic therapy advances for HER2-positive and triple negative breast cancer: what the surgeon needs to know","volume":"24","author":"Downs-Canner","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.surg.2025.109907_bib12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.surg.2025.109907_bib13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib15","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1245\/s10434-021-10441-z","article-title":"A national survey of breast surgeons and radiation oncologists on contemporary axillary management in mastectomy patients","volume":"28","author":"Cortina","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.hoc.2022.08.005","article-title":"Surgical management of the axilla for breast cancer","volume":"37","author":"Laws","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.surg.2025.109907_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/tbj.14226","article-title":"Extrapolation of ACOSOG Z0011 trial results: a survey of breast cancer providers","volume":"27","author":"Weiss","year":"2021","journal-title":"Breast J"},{"key":"10.1016\/j.surg.2025.109907_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2018.1908","article-title":"Surgeon attitudes toward the omission of axillary dissection in early breast cancer","volume":"4","author":"Morrow","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib19","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1245\/s10434-024-14914-9","article-title":"Does neoadjuvant chemotherapy in clinical T1\u2013T2 N0 triple-negative breast cancer increase the extent of axillary surgery?","volume":"31","author":"Cortina","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamasurg.2018.0492","article-title":"Practical guide to surgical data sets: National Cancer Database (NCDB)","volume":"153","author":"Merkow","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2025.109907_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12609-024-00541-6","article-title":"Breast cancer subtypes: clinicopathologic features and treatment considerations","volume":"16","author":"Cobb","year":"2024","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.surg.2025.109907_bib22","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1245\/s10434-022-12123-w","article-title":"Primary breast neuroendocrine tumors: an analysis of the National Cancer Database","volume":"29","author":"Martinez","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jss.2021.02.020","article-title":"Prognostic outcomes of signet ring cell carcinoma of the breast","volume":"264","author":"Mehdi","year":"2021","journal-title":"J Surg Res"},{"key":"10.1016\/j.surg.2025.109907_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109907_bib25","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1245\/s10434-018-6587-2","article-title":"The association of extent of axillary surgery and survival in women with N2\u20133 invasive breast cancer","volume":"25","author":"Park","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jss.2022.10.092","article-title":"Tolerance and outcomes of neoadjuvant chemotherapy in geriatric breast cancer patients","volume":"283","author":"Brown","year":"2023","journal-title":"J Surg Res"},{"key":"10.1016\/j.surg.2025.109907_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-023-07114-8","article-title":"National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial","volume":"203","author":"Rogers","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2025.109907_bib28","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1245\/s10434-021-11260-y","article-title":"Sociodemographic and clinical predictors of neoadjuvant chemotherapy in cT1\u2013T2\/N0 HER2-amplified breast cancer","volume":"29","author":"Duchesneau","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2025.109907_bib31","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1245\/s10434-023-13898-2","article-title":"Intraoperative pathology assessment may lead to overtreatment of the axilla in clinically node-negative breast cancer patients undergoing upfront mastectomy","volume":"30","author":"Pride","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib32","unstructured":"Boughey JC, Haffty B, Buchholz T, et al. Alliance A011202: a Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1\u20133 N1) Who Have Positive Sentinel Lymph Node Disease After Receiving Neoadjuvant Chemotherapy. https:\/\/www.allianceforclinicaltrialsinoncology.org\/main\/cmsfile?cmsPath=\/Public\/Annual%20Meeting\/files\/A011202-Boughey-May2019.pdf. Accessed January 6, 2024."},{"key":"10.1016\/j.surg.2025.109907_bib33","first-page":"1","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study","volume":"42","author":"Montagna","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib34","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1245\/s10434-024-15712-z","article-title":"The prevalence of sentinel lymph node positivity and implications for the utility of frozen section diagnosis following neoadjuvant systemic therapy in patients with clinically node-negative HER2-positive or triple-negative breast cancer","volume":"31","author":"Wanis","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109907_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12282-022-01409-2","article-title":"Conservative axillary surgery is emerging in the surgical management of breast cancer","volume":"30","author":"Noguchi","year":"2023","journal-title":"Breast Cancer"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025007597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025007597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:18:15Z","timestamp":1781511495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606025007597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"alternative-id":["S0039606025007597"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2025.109907","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does neoadjuvant systemic therapy in clinical T1\u20132 N0 human epidermal growth factor receptor 2\u2013positive breast cancer increase the extent of axillary surgery?","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2025.109907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109907"}}